Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

AIMS: Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20‐positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The pharmacokinetics and pharmacodynamics of ocrelizumab i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Gibiansky, Ekaterina, Petry, Claire, Mercier, Francois, Günther, Andreas, Herman, Ann, Kappos, Ludwig, Hauser, Stephen, Yamamoto, Yumi, Wang, Qing, Model, Fabian, Kletzl, Heidemarie
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247316/
https://ncbi.nlm.nih.gov/pubmed/33202059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14658
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados